From TGA website:27 May 2020: The TGA is updating the below...

From TGA website:
27 May 2020: The TGA is updating the below advice regarding hydroxychloroquine use in treating COVID-19. Based on the latest international data, use of hydroxychloroquine to treat COVID-19 is strongly discouraged, including in hospitalised patients, unless the patient is enrolled in a clinical trial which will have safety monitoring protocols and oversight by a Human Research Ethics Committee. It is important to note that the number of COVID-19 patients currently hospitalised in Australia is very low.

Sanofi, the supplier of one of the hydroxychloroquine products marketed in Australia (Plaquenil), has also written to health professionals reinforcing that hydroxychloroquine is not approved for use in Australia for treatment of COVID-19 outside the confines of a clinical trial. Sanofi also reinforced some of the known risks of prescribing hydroxychloroquine, in particular potentially serious cardiac issues. Globally, Sanofi has received an increased number of reports of serious cardiac issues, including deaths, in patients treated with hydroxychloroquine, This appears to be more common in patients also treated with other medicines that can affect the heart.

10 July 2020 The Therapeutic Goods Administration (TGA) has granted provisional approval to remdesivir ("Veklury", Gilead Sciences Pty Ltd) as the first treatment option for COVID-19. It has received provisional approval for use in adults and adolescent patients with severe COVID-19 symptoms who have been hospitalised.